QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

Post-LOE

hydrochlorothiazide; quinapril hydrochloride

PharmaIN

ANDAORALTABLET

Approved

Mar 2005

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE (hydrochlorothiazide; quinapril hydrochloride) by PharmaIN is mechanism of action lisinopril inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension. First approved in 2005.

Drug data last refreshed 19h ago

Mechanism of Action

Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the…

Indications (1)

Worked on QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.